From: Incidence of hypothyroidism after treatment for breast cancer—a Danish matched cohort study
Breast cancer survivors | Matched controls | |||
---|---|---|---|---|
Numbers | % | Numbers | % | |
Total | 44,574 | 100.0 | 203,306 | 100.0 |
Calendar year of diagnosis | ||||
1996–1999 | 11,261 | 25.3 | 52,931 | 26.04 |
2000–2003 | 12,285 | 27.6 | 56,836 | 27.96 |
2004–2006 | 9458 | 21.2 | 42,819 | 21.06 |
2007–2009 | 11,570 | 26.0 | 50,720 | 24.95 |
Age at breast cancer diagnosis, years | ||||
35–39 | 1367 | 3.1 | 6550 | 3.22 |
40–49 | 7123 | 16.0 | 34,454 | 16.95 |
50–59 | 12,543 | 28.1 | 58,850 | 28.95 |
60–69 | 12,945 | 29.0 | 58,230 | 28.64 |
70–79 | 7704 | 17.3 | 33,091 | 16.28 |
80 or older | 2892 | 6.5 | 12,131 | 5.97 |
Charlson comorbidity index (modified)1 | ||||
No | 35,832 | 80.39 | 173,470 | 85.32 |
Low | 7083 | 15.89 | 27,111 | 13.34 |
High | 1659 | 3.72 | 2725 | 1.34 |
Menopausal status at diagnosis | ||||
Unknown | 62 | 0.1 | ||
Premenopausal | 10,833 | 24.3 | ||
Postmenopausal | 33,679 | 75.6 | ||
Tumour size, mm | ||||
Unknown | 2263 | 5.08 | ||
Under 21 | 24,622 | 55.24 | ||
21–50 | 16,033 | 35.97 | ||
Over 50 | 1656 | 3.72 | ||
Lymph node status, numbers | ||||
Unknown | 2903 | 6.51 | ||
N0 | 21,757 | 48.81 | ||
N1–3 | 12,531 | 28.11 | ||
N4+ | 7383 | 16.56 | ||
UICC stage | ||||
Unknown | 3244 | 7.3 | ||
I | 15,357 | 34.5 | ||
II | 18,246 | 40.9 | ||
III | 7727 | 17.3 | ||
Histological grade | ||||
Unknown | 8376 | 18.79 | ||
Low | 11,664 | 26.17 | ||
Moderate | 16,206 | 36.36 | ||
High | 8328 | 18.68 | ||
ER status | ||||
Unknown | 2562 | 5.75 | ||
ER negative (0–9%) | 8320 | 18.67 | ||
ER positive (≥ 10%) | 33,692 | 75.59 | ||
HER2 status2 | ||||
Unknown | 28,005 | 62.83 | ||
Negative | 13,429 | 30.13 | ||
Positive | 3140 | 7.04 |